Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag A new single-pill HIV treatment proved as effective as current multi-pill regimens, with no new safety issues.

flag Gilead Sciences' Phase 3 ARTISTRY-1 trial found a single-tablet HIV regimen combining bictegravir and lenacapavir was non-inferior to current multi-pill treatments in virologically suppressed adults, maintaining HIV-1 RNA below 50 copies/mL at week 48. flag The regimen was well-tolerated with no new safety concerns. flag Top-line results from the ongoing ARTISTRY-2 trial, evaluating the same regimen in patients on Biktarvy, are expected by year-end. flag Gilead plans to submit data to regulators.

3 Articles